Biotage AB
STO:BIOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3), the stock would be worth kr143.2 (0% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3 | kr143.2 |
0%
|
| 3-Year Average | 3 | kr143.2 |
0%
|
| 5-Year Average | 4.1 | kr195.02 |
+36%
|
| Industry Average | 3 | kr143.2 |
0%
|
| Country Average | 2.2 | kr104.78 |
-27%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Biotage AB
STO:BIOT
|
11.5B SEK | 3 | 45 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 132.2 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.4 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 2.4 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 4.1 | 17.2 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 3.8 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.7 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 11.5 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 4.2 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | -1 087.5 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.2 |
| 70th Percentile | 3.7 |
| Max | 283.3 |
Other Multiples
Biotage AB
Glance View
Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.